董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Kyle Armbrester Chief Executive Officer and Director 35 1495.03万美元 未持股 2021-02-12
Matthew S. Holt Chairman 44 未披露 未持股 2021-02-12
Taj J. Clayton Director 44 16.30万美元 未持股 2021-02-12
Kevin M. McNamara Director 64 未披露 未持股 2021-02-12
Kyle B. Peterson Director 35 未披露 未持股 2021-02-12
Vivian E. Riefberg Director 60 18.38万美元 未持股 2021-02-12
Stephen F. Wiggins Director 64 未披露 未持股 2021-02-12
Albert A. Notini Director 63 未披露 未持股 2021-02-12
Brandon H. Hull Director 60 50.00万美元 未持股 2021-02-12
Kevin M. Mcnamara Director 65 24.70万美元 未持股 2021-02-12

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Kyle Armbrester Chief Executive Officer and Director 35 1495.03万美元 未持股 2021-02-12
Steven Senneff President, Chief Financial and Administrative Officer 51 331.89万美元 未持股 2021-02-12
Adam McAnaney General Counsel and Secretary 43 未披露 未持股 2021-02-12
Marc Rothman Chief Medical Officer 50 未披露 未持股 2021-02-12
Peter Boumenot Chief Product Officer 42 未披露 未持股 2021-02-12
David Pierre Chief Operating Officer 41 未披露 未持股 2021-02-12
Josh Builder Chief Technology Officer 39 未披露 未持股 2021-02-12
Laurel Douty Executive Vice President, Clinical Operations, Episodes of Care Services 52 未披露 未持股 2021-02-12

董事简历

中英对照 |  中文 |  英文
Kyle Armbrester

Kyle Armbrester,曾一直担任我们高级副总裁兼首席产品官(2015年9月以来),在那里他曾监管新兴产品的开发和商业化、the More Disruption Please(MDP)催化剂、市场项目和企业发展。从2015年5月到2015年9月,他担任我们临时首席产品官。担任现任职务之前,他曾担任我们的商业开发主管(从2012年1月到2013年7月),随后担任我们的商业开发副总裁(2013年7月至2015年5月),在那里他曾负责战略合作伙伴关系、合并和收购、MDP计划。加入AthenaHealth之前,他曾担任多种技术和卫生技术咨询和战略职务,也曾担任马萨诸塞州的州长查理·贝克竞选的首席信息官。他此前曾创立两个云计算公司。他持有Harvard College的学士学位,以及哈佛大学商学院(Harvard Business School)的工商管理硕士学位。


Kyle Armbrester has served as Chief Executive Officer and a Director of the Company since April 2018. Prior to this, Mr. Armbrester was at athenahealth, where he served as Senior Vice President and Chief Product Officer from May 2015 to April 2018 leading the core product and operations division, and Vice President, Strategy & Corporate Development from May 2011 to May 2015 driving corporate development through strategic partnerships and investments. He has been a Director at The Mentor Network since September 2019 and Parexel International since November 2017. Mr. Armbrester holds an MBA from Harvard Business School and an AB in Government from Harvard University.
Kyle Armbrester,曾一直担任我们高级副总裁兼首席产品官(2015年9月以来),在那里他曾监管新兴产品的开发和商业化、the More Disruption Please(MDP)催化剂、市场项目和企业发展。从2015年5月到2015年9月,他担任我们临时首席产品官。担任现任职务之前,他曾担任我们的商业开发主管(从2012年1月到2013年7月),随后担任我们的商业开发副总裁(2013年7月至2015年5月),在那里他曾负责战略合作伙伴关系、合并和收购、MDP计划。加入AthenaHealth之前,他曾担任多种技术和卫生技术咨询和战略职务,也曾担任马萨诸塞州的州长查理·贝克竞选的首席信息官。他此前曾创立两个云计算公司。他持有Harvard College的学士学位,以及哈佛大学商学院(Harvard Business School)的工商管理硕士学位。
Kyle Armbrester has served as Chief Executive Officer and a Director of the Company since April 2018. Prior to this, Mr. Armbrester was at athenahealth, where he served as Senior Vice President and Chief Product Officer from May 2015 to April 2018 leading the core product and operations division, and Vice President, Strategy & Corporate Development from May 2011 to May 2015 driving corporate development through strategic partnerships and investments. He has been a Director at The Mentor Network since September 2019 and Parexel International since November 2017. Mr. Armbrester holds an MBA from Harvard Business School and an AB in Government from Harvard University.
Matthew S. Holt

Matthew S.Holt自2017年12月起担任董事会主席。Holt先生担任New Mountain Capital LLC的董事总经理兼私募股权总裁。自2001年8月以来,他一直专注于梦百合产品、健康技术、材料和基础设施等一系列行业的成长型收购。霍尔特先生目前在Avantor,Inc.的董事会任职,他还在该公司的薪酬委员会任职。Holt先生担任Ciox Health,CloudMed,Cytel,EMIDS,Ontario Systems,W20and ZEP,Inc.的首席董事或董事长。他还担任Aceto、Topic Pharmaceuticals、TRC Companies的董事。他此前曾担任柏勒罗丰治疗公司公司、Convey Health Solutions公司、Equian公司、Gelest公司、Ikaria公司、Nusil Technology公司的首席董事,以及MailSouth公司的董事。Holt先生拥有哈佛学院(Harvard College)英美文学和语言学士学位。


Matthew S. Holt has served as Chairman of our Board since December 2017. Mr. Holt serves as a Managing Director and President, Private Equity of New Mountain Capital LLC. Since August 2001 he has focused on growth buyouts across a range of industries including healthcare products, health technology, materials and infrastructure. Mr. Holt currently serves on the board of Avantor, Inc., where he also serves on the Compensation Committee. Mr. Holt serves as Lead Director or Chairman of CIOX Health, Cloudmed, Cytel, Emids, Ontario Systems, W20 and Zep, Inc. He also serves as a Director of Aceto, Topic Pharmaceuticals, and TRC Companies. He previously served as Lead Director of Bellerophon Therapeutics, Inc., Convey Health Solutions, Inc., Equian LLC, Gelest, Ikaria, Inc., Nusil Technology LLC and as a Director of MailSouth. Mr. Holt holds an AB in English and American Literature and Language from Harvard College.
Matthew S.Holt自2017年12月起担任董事会主席。Holt先生担任New Mountain Capital LLC的董事总经理兼私募股权总裁。自2001年8月以来,他一直专注于梦百合产品、健康技术、材料和基础设施等一系列行业的成长型收购。霍尔特先生目前在Avantor,Inc.的董事会任职,他还在该公司的薪酬委员会任职。Holt先生担任Ciox Health,CloudMed,Cytel,EMIDS,Ontario Systems,W20and ZEP,Inc.的首席董事或董事长。他还担任Aceto、Topic Pharmaceuticals、TRC Companies的董事。他此前曾担任柏勒罗丰治疗公司公司、Convey Health Solutions公司、Equian公司、Gelest公司、Ikaria公司、Nusil Technology公司的首席董事,以及MailSouth公司的董事。Holt先生拥有哈佛学院(Harvard College)英美文学和语言学士学位。
Matthew S. Holt has served as Chairman of our Board since December 2017. Mr. Holt serves as a Managing Director and President, Private Equity of New Mountain Capital LLC. Since August 2001 he has focused on growth buyouts across a range of industries including healthcare products, health technology, materials and infrastructure. Mr. Holt currently serves on the board of Avantor, Inc., where he also serves on the Compensation Committee. Mr. Holt serves as Lead Director or Chairman of CIOX Health, Cloudmed, Cytel, Emids, Ontario Systems, W20 and Zep, Inc. He also serves as a Director of Aceto, Topic Pharmaceuticals, and TRC Companies. He previously served as Lead Director of Bellerophon Therapeutics, Inc., Convey Health Solutions, Inc., Equian LLC, Gelest, Ikaria, Inc., Nusil Technology LLC and as a Director of MailSouth. Mr. Holt holds an AB in English and American Literature and Language from Harvard College.
Taj J. Clayton

Taj J.Clayton自2020年7月起担任公司董事。Clayton先生自2020年7月起担任New Mountain Capital执行咨询委员会成员。自2020年9月以来,Clayton先生一直担任Kirkland&Ellis LLP的合伙人。此前,他曾担任Winston&Strawn,LLP的合伙人(2017年3月至2020年8月)。2006年9月至2013年12月,他是合伙人,2014年1月至2017年3月,他是校长,从2005年9月到2006年9月,Clayton先生在Fish&Richardson P.C.担任马萨诸塞州美国联邦地区法院首席法官Mark L.Wolf的书记官。Clayton先生是UT Southwestern Medical Center的总裁顾问委员会成员,国际预防和解决冲突研究所的董事会成员,Girls Inc.的国家董事会成员,the Hockaday School的董事会成员,以及the Coalition of Black Excellence的顾问委员会成员。Clayton先生持有Harvard Law School法学博士学位和Harvard University历史学AB学位。


Taj J. Clayton has served as a Director of the Company since July 2020. Mr. Clayton has served as a member of the Executive Advisory Council of New Mountain Capital since July 2020. Since September 2020 Mr. Clayton has served as a Partner at Kirkland & Ellis LLP. Prior to this, from March 2017 to August 2020 he was a Partner at Winston & Strawn, LLP. From September 2006 to December 2013 he was an Associate, and from January 2014 to March 2017 a Principal, at Fish & Richardson P.C. From September 2005 to September 2006 Mr. Clayton served as a Law Clerk to Chief Judge Mark L. Wolf in the United States Federal District Court of Massachusetts. Mr. Clayton is a member of the President’s Advisory Board for UT Southwestern Medical Center, a Member of the Board for the International Institute for Conflict Prevention and Resolution, a Member of the National Board of Directors for Girls Inc., a Member of the Board of the Hockaday School and a Member of the Advisory Board for the Coalition of Black Excellence. Mr. Clayton holds a JD from Harvard Law School and an AB in History from Harvard University.
Taj J.Clayton自2020年7月起担任公司董事。Clayton先生自2020年7月起担任New Mountain Capital执行咨询委员会成员。自2020年9月以来,Clayton先生一直担任Kirkland&Ellis LLP的合伙人。此前,他曾担任Winston&Strawn,LLP的合伙人(2017年3月至2020年8月)。2006年9月至2013年12月,他是合伙人,2014年1月至2017年3月,他是校长,从2005年9月到2006年9月,Clayton先生在Fish&Richardson P.C.担任马萨诸塞州美国联邦地区法院首席法官Mark L.Wolf的书记官。Clayton先生是UT Southwestern Medical Center的总裁顾问委员会成员,国际预防和解决冲突研究所的董事会成员,Girls Inc.的国家董事会成员,the Hockaday School的董事会成员,以及the Coalition of Black Excellence的顾问委员会成员。Clayton先生持有Harvard Law School法学博士学位和Harvard University历史学AB学位。
Taj J. Clayton has served as a Director of the Company since July 2020. Mr. Clayton has served as a member of the Executive Advisory Council of New Mountain Capital since July 2020. Since September 2020 Mr. Clayton has served as a Partner at Kirkland & Ellis LLP. Prior to this, from March 2017 to August 2020 he was a Partner at Winston & Strawn, LLP. From September 2006 to December 2013 he was an Associate, and from January 2014 to March 2017 a Principal, at Fish & Richardson P.C. From September 2005 to September 2006 Mr. Clayton served as a Law Clerk to Chief Judge Mark L. Wolf in the United States Federal District Court of Massachusetts. Mr. Clayton is a member of the President’s Advisory Board for UT Southwestern Medical Center, a Member of the Board for the International Institute for Conflict Prevention and Resolution, a Member of the National Board of Directors for Girls Inc., a Member of the Board of the Hockaday School and a Member of the Advisory Board for the Coalition of Black Excellence. Mr. Clayton holds a JD from Harvard Law School and an AB in History from Harvard University.
Kevin M. McNamara
暂无中文简介

Kevin M. McNamara has served as a Director of the Company since April 2013. He previously served as the Chief Executive Officer of CenseoHealth from February 2015 to June 2018. Mr. McNamara has served as the Founding Principal at McNamara Family Ventures since June 2012. From April 2013 to October 2014 he was an Operating Partner at Health Evolution Partners. He has been a Director of Tyson Foods, Inc. since August 2007 and currently serves as the Vice Chairman and Lead Independent Director. He has served as a Director of Luminex Corporation since May 2003. Mr. McNamara previously served on the Board of Leon Medical Centers, Agilum Healthcare Intelligence and Optimal Radiology Partners. Mr. McNamara holds a BS in Accounting from Virginia Commonwealth University and an MBA from the University of Richmond.
暂无中文简介
Kevin M. McNamara has served as a Director of the Company since April 2013. He previously served as the Chief Executive Officer of CenseoHealth from February 2015 to June 2018. Mr. McNamara has served as the Founding Principal at McNamara Family Ventures since June 2012. From April 2013 to October 2014 he was an Operating Partner at Health Evolution Partners. He has been a Director of Tyson Foods, Inc. since August 2007 and currently serves as the Vice Chairman and Lead Independent Director. He has served as a Director of Luminex Corporation since May 2003. Mr. McNamara previously served on the Board of Leon Medical Centers, Agilum Healthcare Intelligence and Optimal Radiology Partners. Mr. McNamara holds a BS in Accounting from Virginia Commonwealth University and an MBA from the University of Richmond.
Kyle B. Peterson

Kyle B.Peterson自2017年12月起担任公司董事。他担任New Mountain Capital的董事总经理,并一直任职公司(2011年9月以来)。此前,2009年8月至2011年9月,他是Sageview Capital的投资专业人员。加入Sageview之前,Peterson从2006年6月到2009年7月在Merrill Lynch并购集团任职。他目前自2017年11月起担任Cytel的董事会主席,自2019年11月起担任Horizon Services的董事会董事,此前曾于2015年11月至2019年7月担任Equian的董事会成员,并于2019年1月至2019年11月担任Remedy Partners的董事会成员。Peterson先生在康奈尔大学(Cornell University)获得学士学位。


Kyle B. Peterson has served as Director of the Company since December 2017. He serves as a Managing Director of New Mountain Capital and has been with the firm since September 2011. Prior to this, he was an investment professional at Sageview Capital from August 2009 to September 2011. Prior to Sageview, Mr. Peterson worked in the Mergers and Acquisitions group at Merrill Lynch from June 2006 to July 2009. He currently serves as Chairman of the Board of Directors of Cytel since November 2017 as a Director on the board of Horizon Services since November 2019 and formerly served on the boards of Equian from November 2015 to July 2019 and Remedy Partners from January 2019 to November 2019. Mr. Peterson received his B.S. from Cornell University.
Kyle B.Peterson自2017年12月起担任公司董事。他担任New Mountain Capital的董事总经理,并一直任职公司(2011年9月以来)。此前,2009年8月至2011年9月,他是Sageview Capital的投资专业人员。加入Sageview之前,Peterson从2006年6月到2009年7月在Merrill Lynch并购集团任职。他目前自2017年11月起担任Cytel的董事会主席,自2019年11月起担任Horizon Services的董事会董事,此前曾于2015年11月至2019年7月担任Equian的董事会成员,并于2019年1月至2019年11月担任Remedy Partners的董事会成员。Peterson先生在康奈尔大学(Cornell University)获得学士学位。
Kyle B. Peterson has served as Director of the Company since December 2017. He serves as a Managing Director of New Mountain Capital and has been with the firm since September 2011. Prior to this, he was an investment professional at Sageview Capital from August 2009 to September 2011. Prior to Sageview, Mr. Peterson worked in the Mergers and Acquisitions group at Merrill Lynch from June 2006 to July 2009. He currently serves as Chairman of the Board of Directors of Cytel since November 2017 as a Director on the board of Horizon Services since November 2019 and formerly served on the boards of Equian from November 2015 to July 2019 and Remedy Partners from January 2019 to November 2019. Mr. Peterson received his B.S. from Cornell University.
Vivian E. Riefberg

Vivian E.Riefberg自2020年2月起担任公司董事。自2020年8月以来,她一直担任David C.Walentas Jefferson Scholars Foundation教授职位,并担任弗吉尼亚大学达顿商学院的实践教授。在此之前,Riefberg女士于1987年9月至2020年5月在麦肯锡公司(McKinsey&Company)任职,并担任多个高级职位,包括领导美洲的公共部门实践并共同领导美国医疗保健实践。她目前自2020年6月起担任麦肯锡公司(McKinsey&Company)的名誉董事兼高级顾问。2018年,Riefberg女士当选为公共广播服务董事会董事。自2020年7月起,她还担任约翰·霍普金斯医学公司董事会成员。她此前曾担任the NIH Clinical Center的董事会成员,以及the Partnership for a Health America,Mentors,Inc.和McKinsey&Company的董事。Riefberg女士拥有Harvard Business School工商管理硕士学位和Harvard University历史学学士学位。


Vivian E. Riefberg,has served as a member of Waystar Holding Corp. board of directors since October 2023. Since August 2020, she has also served as the David C. Walentas Jefferson Scholars Foundation Professorship Chair and is a Professor of Practice at the University of Virginia ("UVA") Darden School of Business and a Fellow at The Miller Center at UVA. Ms. Riefberg previously held a variety of high-ranking executive positions at McKinsey & Company from September 1987 to July 1988 and December 1989 to May 2020, including leading the Public Sector Practice for the Americas and co-leading the U.S. Health Care practice. She also currently serves on the boards of ONWARD Medical N.V. since 2022 and Lightrock, an impact investing fund, since 2022 and privately held Accompany Health, Inc. since 2023 and K Health Inc. since 2021, and has served as an Emeritus Director with McKinsey & Company since June 2020. In the non-profit world, she serves on the boards of the Public Broadcasting Service since 2018, Johns Hopkins Medicine since July 2020, and the advisory board for the Smithsonian American Women's History Museum since August 2021. She was previously on the board of governors for the NIH Clinical Center from 2000 to 2004 and was a director on the boards for Signify Health, Inc. from 2020 to 2023, the Partnership for a Healthier America, and McKinsey & Company.
Vivian E.Riefberg自2020年2月起担任公司董事。自2020年8月以来,她一直担任David C.Walentas Jefferson Scholars Foundation教授职位,并担任弗吉尼亚大学达顿商学院的实践教授。在此之前,Riefberg女士于1987年9月至2020年5月在麦肯锡公司(McKinsey&Company)任职,并担任多个高级职位,包括领导美洲的公共部门实践并共同领导美国医疗保健实践。她目前自2020年6月起担任麦肯锡公司(McKinsey&Company)的名誉董事兼高级顾问。2018年,Riefberg女士当选为公共广播服务董事会董事。自2020年7月起,她还担任约翰·霍普金斯医学公司董事会成员。她此前曾担任the NIH Clinical Center的董事会成员,以及the Partnership for a Health America,Mentors,Inc.和McKinsey&Company的董事。Riefberg女士拥有Harvard Business School工商管理硕士学位和Harvard University历史学学士学位。
Vivian E. Riefberg,has served as a member of Waystar Holding Corp. board of directors since October 2023. Since August 2020, she has also served as the David C. Walentas Jefferson Scholars Foundation Professorship Chair and is a Professor of Practice at the University of Virginia ("UVA") Darden School of Business and a Fellow at The Miller Center at UVA. Ms. Riefberg previously held a variety of high-ranking executive positions at McKinsey & Company from September 1987 to July 1988 and December 1989 to May 2020, including leading the Public Sector Practice for the Americas and co-leading the U.S. Health Care practice. She also currently serves on the boards of ONWARD Medical N.V. since 2022 and Lightrock, an impact investing fund, since 2022 and privately held Accompany Health, Inc. since 2023 and K Health Inc. since 2021, and has served as an Emeritus Director with McKinsey & Company since June 2020. In the non-profit world, she serves on the boards of the Public Broadcasting Service since 2018, Johns Hopkins Medicine since July 2020, and the advisory board for the Smithsonian American Women's History Museum since August 2021. She was previously on the board of governors for the NIH Clinical Center from 2000 to 2004 and was a director on the boards for Signify Health, Inc. from 2020 to 2023, the Partnership for a Healthier America, and McKinsey & Company.
Stephen F. Wiggins

Stephen F.Wiggins自2019年11月起担任公司董事。Wiggins先生是一位企业家和私人投资者。自2018年5月以来,他一直担任Wiggins Ventures的创始人兼董事长。2011年9月至2019年1月,他是Remedy Partners的创始人兼董事长。2008年3月至2019年8月,他担任EW梦百合Partners的董事总经理。他此前曾担任HealthMarket公司(从1999年9月到2004年4月)、Oxford Health Plans公司(从1984年9月到2000年12月)的创始人、主席兼首席执行官。Wiggins先生拥有Harvard Business School工商管理硕士学位和Macalester College城市研究学士学位。


Stephen F. Wiggins has served as a Director of the Company since November 2019. Mr. Wiggins is an entrepreneur and private investor. Since May 2018 he has served as the Founder and Chairman of Wiggins Ventures. From September 2011 to January 2019 he was the Founder and Chairman of Remedy Partners. From March 2008 to August 2019 he was a Managing Director at EW Healthcare Partners. He was previously the Founder, Chairman and CEO of HealthMarket from September 1999 to April 2004 and Oxford Health Plans from September 1984 to December 2000. Mr. Wiggins holds an MBA from Harvard Business School and a BA in Urban Studies from Macalester College.
Stephen F.Wiggins自2019年11月起担任公司董事。Wiggins先生是一位企业家和私人投资者。自2018年5月以来,他一直担任Wiggins Ventures的创始人兼董事长。2011年9月至2019年1月,他是Remedy Partners的创始人兼董事长。2008年3月至2019年8月,他担任EW梦百合Partners的董事总经理。他此前曾担任HealthMarket公司(从1999年9月到2004年4月)、Oxford Health Plans公司(从1984年9月到2000年12月)的创始人、主席兼首席执行官。Wiggins先生拥有Harvard Business School工商管理硕士学位和Macalester College城市研究学士学位。
Stephen F. Wiggins has served as a Director of the Company since November 2019. Mr. Wiggins is an entrepreneur and private investor. Since May 2018 he has served as the Founder and Chairman of Wiggins Ventures. From September 2011 to January 2019 he was the Founder and Chairman of Remedy Partners. From March 2008 to August 2019 he was a Managing Director at EW Healthcare Partners. He was previously the Founder, Chairman and CEO of HealthMarket from September 1999 to April 2004 and Oxford Health Plans from September 1984 to December 2000. Mr. Wiggins holds an MBA from Harvard Business School and a BA in Urban Studies from Macalester College.
Albert A. Notini

Albert A. Notini,2005年8月起,担任董事;2007年8月起,担任New Mountain Capital的高级顾问。2007年8月至2011年6月,他担任Apptis, Inc.的董事长、首席执行官,这是信息技术解决方案与服务提供商。2007年8月之前,他从2004年4月起,担任Sonus Networks, Inc.的总裁、首席运营官、董事,这是语音基础架构产品提供商;2000年5月至2004年3月,担任Manufacturers’ Services Limited的首席财务官、董事长,全球性的电子产品与供应链服务公司。2000年5月前,他曾担任Wang Global, Inc.的企业发展与管理执行副总裁、法律总顾问;后来,该公司被信息技术服务提供商Getronics NV收购,他因而担任后者的执行副总裁。目前,他是下列企业的董事:Camber Corporation、Iron Bow Technologies, LLC、 Valet Waste Holdings, Inc.;曾担任Sonus Networks的董事。他在Boston College获得学士学位,在Boston University 获得硕士学位,在Boston College Law School获得法律博士学位。


Albert A. Notini has served as a Director of the Company since December 2017. Since January 2012 he has served as a Managing Director at New Mountain Capital. Prior to this, he was the Chairman and Chief Executive Officer of Apptis Inc. from March 2007 to June 2011. From April 2004 to August 2007 he was the President and Chief Operating Officer of Sonus Networks, Inc. Mr. Notini currently serves as a Director of Western Dental, CIOX Health, Alteon Health, Sparta Systems, Emids and MAG Aerospace. Mr. Notini holds a JD from Boston College Law School, a MA from Boston University and a BA from Boston College.
Albert A. Notini,2005年8月起,担任董事;2007年8月起,担任New Mountain Capital的高级顾问。2007年8月至2011年6月,他担任Apptis, Inc.的董事长、首席执行官,这是信息技术解决方案与服务提供商。2007年8月之前,他从2004年4月起,担任Sonus Networks, Inc.的总裁、首席运营官、董事,这是语音基础架构产品提供商;2000年5月至2004年3月,担任Manufacturers’ Services Limited的首席财务官、董事长,全球性的电子产品与供应链服务公司。2000年5月前,他曾担任Wang Global, Inc.的企业发展与管理执行副总裁、法律总顾问;后来,该公司被信息技术服务提供商Getronics NV收购,他因而担任后者的执行副总裁。目前,他是下列企业的董事:Camber Corporation、Iron Bow Technologies, LLC、 Valet Waste Holdings, Inc.;曾担任Sonus Networks的董事。他在Boston College获得学士学位,在Boston University 获得硕士学位,在Boston College Law School获得法律博士学位。
Albert A. Notini has served as a Director of the Company since December 2017. Since January 2012 he has served as a Managing Director at New Mountain Capital. Prior to this, he was the Chairman and Chief Executive Officer of Apptis Inc. from March 2007 to June 2011. From April 2004 to August 2007 he was the President and Chief Operating Officer of Sonus Networks, Inc. Mr. Notini currently serves as a Director of Western Dental, CIOX Health, Alteon Health, Sparta Systems, Emids and MAG Aerospace. Mr. Notini holds a JD from Boston College Law School, a MA from Boston University and a BA from Boston College.
Brandon H. Hull

自1999年以来,Brandon H. Hull一直担任我们的董事会成员,自1997年10月,他曾担任 Cardinal Partners合伙人,这是一家风险投资公司,专门从事医疗保健和生命科学领域的风险投资。从1991年至1997,他曾担任Edison Venture Fund的总裁。他担任了Awarepoint公司,CodeRyte公司,FluidNet公司,MDX Medical, Inc., and Replication Medical的董事。他获得惠顿学院文学学士和 Wharton School at the University of Pennsylvania。工商管理硕士学位。


Brandon H. Hull has served as a Director of the Company since April 2018. Since February 2018 Mr. Hull has served as an Industry Advisor for New Mountain Capital. Prior to this, from September 1996 to December 2017 he was the Managing General Partner and Co-Founder of Cardinal Partners. He has served on the Board of Asylon Aerospace since September 2015 and served on the Board of athenahealth as Lead Director from August 1999 to January 2019. He has also previously served as a Director of Equian, Sapphire Digital, Ivenix, QPID, Inc., Cureatr and CodeRyte, among many others. Mr. Hull holds an MBA from the Wharton School of the University of Pennsylvania and a BA in Literature & Philosophy from Wheaton College.
自1999年以来,Brandon H. Hull一直担任我们的董事会成员,自1997年10月,他曾担任 Cardinal Partners合伙人,这是一家风险投资公司,专门从事医疗保健和生命科学领域的风险投资。从1991年至1997,他曾担任Edison Venture Fund的总裁。他担任了Awarepoint公司,CodeRyte公司,FluidNet公司,MDX Medical, Inc., and Replication Medical的董事。他获得惠顿学院文学学士和 Wharton School at the University of Pennsylvania。工商管理硕士学位。
Brandon H. Hull has served as a Director of the Company since April 2018. Since February 2018 Mr. Hull has served as an Industry Advisor for New Mountain Capital. Prior to this, from September 1996 to December 2017 he was the Managing General Partner and Co-Founder of Cardinal Partners. He has served on the Board of Asylon Aerospace since September 2015 and served on the Board of athenahealth as Lead Director from August 1999 to January 2019. He has also previously served as a Director of Equian, Sapphire Digital, Ivenix, QPID, Inc., Cureatr and CodeRyte, among many others. Mr. Hull holds an MBA from the Wharton School of the University of Pennsylvania and a BA in Literature & Philosophy from Wheaton College.
Kevin M. Mcnamara

Kevin M. Mcnamara, 麦克纳马拉家庭创业(为医疗保健公司提供风险投资及资本的家庭投资办事处)创立会长;他2013年4月加入健康合作伙伴(一家医疗保健私募股权投资公司)并担任运营合伙人。在健康合作伙伴任职期间,他担任最佳合作伙伴放射科董事以及 CenseoHealth董事会主席。自2011年起开始担任Agilum医疗情报(一家医疗保健商业智能公司)董事长。他曾于2010年到2011年担任莱昂医疗中心(为佛罗里达州迈阿密 - 戴德县医疗保险的病人提供医疗服务)副董事长并持续担任莱昂医疗中心董事。从2005年到2009年他担任HealthSpring公司(一家管理式医疗公司)执行副总裁和首席财务官以及风险官;Luminex公司董事;自2007年开始担任公司董事。他的金融知识和专业经验对公司董事会、审计和薪酬委员会起着至关重要的作用。根据SEC的规定,他在监督财务报告程序,内部会计及财务监控,以及管理独立审计任务方面的经验使他有资格成为审计委员会金融专家。


Kevin M. Mcnamara,is the founding principal of McNamara Family Ventures, a family investment office providing venture and growth capital to health care companies. He currently serves (since March 2024) as Executive Chairman of Harmony Cares, a private equity-backed healthcare company delivering care to Medicare beneficiaries under value-based care arrangements. He served as a director until March 2023 at SignifyHealth (formerly CenseoHealth), a nationwide leader in physician in-home health assessments, after having served as its Chief Executive Officer from 2015 to June 2018.Mr. McNamara has been a member of the Board since 2007, has served as Lead Independent Director since September 2019 and was appointed Vice Chairman of the Board in February 2020.
Kevin M. Mcnamara, 麦克纳马拉家庭创业(为医疗保健公司提供风险投资及资本的家庭投资办事处)创立会长;他2013年4月加入健康合作伙伴(一家医疗保健私募股权投资公司)并担任运营合伙人。在健康合作伙伴任职期间,他担任最佳合作伙伴放射科董事以及 CenseoHealth董事会主席。自2011年起开始担任Agilum医疗情报(一家医疗保健商业智能公司)董事长。他曾于2010年到2011年担任莱昂医疗中心(为佛罗里达州迈阿密 - 戴德县医疗保险的病人提供医疗服务)副董事长并持续担任莱昂医疗中心董事。从2005年到2009年他担任HealthSpring公司(一家管理式医疗公司)执行副总裁和首席财务官以及风险官;Luminex公司董事;自2007年开始担任公司董事。他的金融知识和专业经验对公司董事会、审计和薪酬委员会起着至关重要的作用。根据SEC的规定,他在监督财务报告程序,内部会计及财务监控,以及管理独立审计任务方面的经验使他有资格成为审计委员会金融专家。
Kevin M. Mcnamara,is the founding principal of McNamara Family Ventures, a family investment office providing venture and growth capital to health care companies. He currently serves (since March 2024) as Executive Chairman of Harmony Cares, a private equity-backed healthcare company delivering care to Medicare beneficiaries under value-based care arrangements. He served as a director until March 2023 at SignifyHealth (formerly CenseoHealth), a nationwide leader in physician in-home health assessments, after having served as its Chief Executive Officer from 2015 to June 2018.Mr. McNamara has been a member of the Board since 2007, has served as Lead Independent Director since September 2019 and was appointed Vice Chairman of the Board in February 2020.

高管简历

中英对照 |  中文 |  英文
Kyle Armbrester

Kyle Armbrester,曾一直担任我们高级副总裁兼首席产品官(2015年9月以来),在那里他曾监管新兴产品的开发和商业化、the More Disruption Please(MDP)催化剂、市场项目和企业发展。从2015年5月到2015年9月,他担任我们临时首席产品官。担任现任职务之前,他曾担任我们的商业开发主管(从2012年1月到2013年7月),随后担任我们的商业开发副总裁(2013年7月至2015年5月),在那里他曾负责战略合作伙伴关系、合并和收购、MDP计划。加入AthenaHealth之前,他曾担任多种技术和卫生技术咨询和战略职务,也曾担任马萨诸塞州的州长查理·贝克竞选的首席信息官。他此前曾创立两个云计算公司。他持有Harvard College的学士学位,以及哈佛大学商学院(Harvard Business School)的工商管理硕士学位。


Kyle Armbrester has served as Chief Executive Officer and a Director of the Company since April 2018. Prior to this, Mr. Armbrester was at athenahealth, where he served as Senior Vice President and Chief Product Officer from May 2015 to April 2018 leading the core product and operations division, and Vice President, Strategy & Corporate Development from May 2011 to May 2015 driving corporate development through strategic partnerships and investments. He has been a Director at The Mentor Network since September 2019 and Parexel International since November 2017. Mr. Armbrester holds an MBA from Harvard Business School and an AB in Government from Harvard University.
Kyle Armbrester,曾一直担任我们高级副总裁兼首席产品官(2015年9月以来),在那里他曾监管新兴产品的开发和商业化、the More Disruption Please(MDP)催化剂、市场项目和企业发展。从2015年5月到2015年9月,他担任我们临时首席产品官。担任现任职务之前,他曾担任我们的商业开发主管(从2012年1月到2013年7月),随后担任我们的商业开发副总裁(2013年7月至2015年5月),在那里他曾负责战略合作伙伴关系、合并和收购、MDP计划。加入AthenaHealth之前,他曾担任多种技术和卫生技术咨询和战略职务,也曾担任马萨诸塞州的州长查理·贝克竞选的首席信息官。他此前曾创立两个云计算公司。他持有Harvard College的学士学位,以及哈佛大学商学院(Harvard Business School)的工商管理硕士学位。
Kyle Armbrester has served as Chief Executive Officer and a Director of the Company since April 2018. Prior to this, Mr. Armbrester was at athenahealth, where he served as Senior Vice President and Chief Product Officer from May 2015 to April 2018 leading the core product and operations division, and Vice President, Strategy & Corporate Development from May 2011 to May 2015 driving corporate development through strategic partnerships and investments. He has been a Director at The Mentor Network since September 2019 and Parexel International since November 2017. Mr. Armbrester holds an MBA from Harvard Business School and an AB in Government from Harvard University.
Steven Senneff

Steven Senneff自2019年11月起担任公司总裁兼首席财务和行政官。在此之前,Senneff先生于2019年3月至2019年11月担任Remedy Partners的首席财务官,并担任DigitalOcean的首席财务官,Inc.于2017年10月至2019年2月负责各自公司的所有会计和财务活动。在Cotiviti,Inc.,他于2012年10月至2014年4月和2015年5月至2017年9月担任首席财务官,负责Cotiviti的所有会计和财务活动,并担任公司上市领导团队的一部分,从2014年5月到2015年4月,他担任首席运营官,在那里他专注于收购后整合期的增长机会。Senneff先生持有Purdue University,Krannert Graduate School of Management的工商管理硕士学位和the University of Iowa的会计学工商管理硕士学位。


Steven Senneff has served as President and Chief Financial and Administrative Officer of the Company since November 2019. Prior to this, Mr. Senneff served as the Chief Financial Officer of Remedy Partners from March 2019 to November 2019 and as the Chief Financial Officer of DigitalOcean, Inc. from October 2017 to February 2019 where he was responsible for all of the accounting and finance activities at the respective companies. At Cotiviti, Inc., he served as Chief Financial Officer from October 2012 to April 2014 and from May 2015 to September 2017 where he was responsible for all of Cotiviti’s accounting and finance activities and part of the leadership team that took the company public, and Chief Operating Officer from May 2014 to April 2015 where he focused on growth opportunities during a post-acquisition integration period. Mr. Senneff holds an MBA from Purdue University, Krannert Graduate School of Management and a BBA in Accounting from the University of Iowa.
Steven Senneff自2019年11月起担任公司总裁兼首席财务和行政官。在此之前,Senneff先生于2019年3月至2019年11月担任Remedy Partners的首席财务官,并担任DigitalOcean的首席财务官,Inc.于2017年10月至2019年2月负责各自公司的所有会计和财务活动。在Cotiviti,Inc.,他于2012年10月至2014年4月和2015年5月至2017年9月担任首席财务官,负责Cotiviti的所有会计和财务活动,并担任公司上市领导团队的一部分,从2014年5月到2015年4月,他担任首席运营官,在那里他专注于收购后整合期的增长机会。Senneff先生持有Purdue University,Krannert Graduate School of Management的工商管理硕士学位和the University of Iowa的会计学工商管理硕士学位。
Steven Senneff has served as President and Chief Financial and Administrative Officer of the Company since November 2019. Prior to this, Mr. Senneff served as the Chief Financial Officer of Remedy Partners from March 2019 to November 2019 and as the Chief Financial Officer of DigitalOcean, Inc. from October 2017 to February 2019 where he was responsible for all of the accounting and finance activities at the respective companies. At Cotiviti, Inc., he served as Chief Financial Officer from October 2012 to April 2014 and from May 2015 to September 2017 where he was responsible for all of Cotiviti’s accounting and finance activities and part of the leadership team that took the company public, and Chief Operating Officer from May 2014 to April 2015 where he focused on growth opportunities during a post-acquisition integration period. Mr. Senneff holds an MBA from Purdue University, Krannert Graduate School of Management and a BBA in Accounting from the University of Iowa.
Adam McAnaney

Adam McAney自2019年11月收购Remedy Partners以来一直担任公司总法律顾问兼秘书。他于2019年6月加入Remedy Partners,担任总法律顾问兼秘书。在加入Remedy Partners之前,McAney曾在安泰担任Vice President,2017年11月至2019年3月担任公司法律主管兼公司秘书,负责监管SEC报告和披露事项、公司融资、并购、子公司管理、许可、投资等方面的法律支持,高管薪酬和人力资源。McAnaney先生此前曾于2013年5月至2017年10月担任Aetna的高级公司法律顾问,并于2011年5月至2012年4月担任法律顾问。从2004年9月到2011年5月,他曾担任Sullivan&Cromwell公司(专注于资本市场和并购)的纽约、法兰克福和伦敦办公室的合伙人。McAney先生拥有哥伦比亚大学法学院(Columbia Law School)法学博士学位和耶鲁大学(Yale University)日耳曼语言和文学学士学位。


Adam McAnaney has served as General Counsel and Secretary of the Company since its acquisition of Remedy Partners in November 2019. He joined Remedy Partners as General Counsel and Secretary in June 2019. Prior to joining Remedy Partners, Mr. McAnaney was at Aetna where he served as Vice President, Head of Corporate Legal and Corporate Secretary from November 2017 to March 2019 overseeing legal support of SEC reporting and disclosure matters, corporate finance, mergers and acquisitions, subsidiary management, licensing, investments, executive compensation and human resources. Mr. McAnaney previously held the positions of Senior Corporate Counsel from May 2013 to October 2017 and Counsel from May 2011 to April 2012 at Aetna. From September 2004 to May 2011 he was an Associate in the New York, Frankfurt and London offices of Sullivan & Cromwell LLP focusing on capital markets and mergers and acquisitions. Mr. McAnaney holds a JD from Columbia Law School and a BA in Germanic Languages and Literatures from Yale University.
Adam McAney自2019年11月收购Remedy Partners以来一直担任公司总法律顾问兼秘书。他于2019年6月加入Remedy Partners,担任总法律顾问兼秘书。在加入Remedy Partners之前,McAney曾在安泰担任Vice President,2017年11月至2019年3月担任公司法律主管兼公司秘书,负责监管SEC报告和披露事项、公司融资、并购、子公司管理、许可、投资等方面的法律支持,高管薪酬和人力资源。McAnaney先生此前曾于2013年5月至2017年10月担任Aetna的高级公司法律顾问,并于2011年5月至2012年4月担任法律顾问。从2004年9月到2011年5月,他曾担任Sullivan&Cromwell公司(专注于资本市场和并购)的纽约、法兰克福和伦敦办公室的合伙人。McAney先生拥有哥伦比亚大学法学院(Columbia Law School)法学博士学位和耶鲁大学(Yale University)日耳曼语言和文学学士学位。
Adam McAnaney has served as General Counsel and Secretary of the Company since its acquisition of Remedy Partners in November 2019. He joined Remedy Partners as General Counsel and Secretary in June 2019. Prior to joining Remedy Partners, Mr. McAnaney was at Aetna where he served as Vice President, Head of Corporate Legal and Corporate Secretary from November 2017 to March 2019 overseeing legal support of SEC reporting and disclosure matters, corporate finance, mergers and acquisitions, subsidiary management, licensing, investments, executive compensation and human resources. Mr. McAnaney previously held the positions of Senior Corporate Counsel from May 2013 to October 2017 and Counsel from May 2011 to April 2012 at Aetna. From September 2004 to May 2011 he was an Associate in the New York, Frankfurt and London offices of Sullivan & Cromwell LLP focusing on capital markets and mergers and acquisitions. Mr. McAnaney holds a JD from Columbia Law School and a BA in Germanic Languages and Literatures from Yale University.
Marc Rothman

Marc Rothman自2020年6月起担任公司首席医疗官。在此之前,罗斯曼博士于2019年5月至2020年6月担任Aspire梦百合的副首席医疗官,在那里他领导了一项全国性的姑息治疗医疗实践,并实施和发展了新的临床模式和业务线。在此之前,罗斯曼博士于2015年1月至2018年12月担任KindredHealthcare,Inc.企业首席医疗官他也曾担任Kindred’;的护理中心部门的首席医疗官(从2011年11月到2014年12月),在那里他最终领导医疗和药房领导团队。Rothman博士拥有纽约大学医学院(New York University School of Medicine)的医学博士学位和麦迪逊威斯康星大学(University of Wisconsin,Madison)的哲学学士学位。他完成了耶鲁大学纽黑文医院(Yale New Haven Hospital)的研究生临床培训,并在内科、老年病学和临终关怀与姑息医学三个专业获得三个学位。


Marc Rothman has served as Chief Medical Officer of the Company since June 2020. Prior to this, Dr. Rothman served as Deputy Chief Medical Officer at Aspire Healthcare from May 2019 to June 2020 where he led a nationwide palliative care medical practice and implemented and grew new clinical models and business lines. Before that Dr. Rothman served as Enterprise Chief Medical Officer from January 2015 to December 2018 at Kindred Healthcare, Inc. He also served as the Chief Medical Officer of Kindred’s Nursing Center Division from November 2011 to December 2014 where he eventually led the medical and pharmacy leadership team. Dr. Rothman holds an MD from New York University School of Medicine and a BA in Philosophy from the University of Wisconsin, Madison. He completed his postgraduate clinical training at Yale New Haven Hospital and is triple boarded in Internal, Geriatric and Hospice & Palliative Medicine.
Marc Rothman自2020年6月起担任公司首席医疗官。在此之前,罗斯曼博士于2019年5月至2020年6月担任Aspire梦百合的副首席医疗官,在那里他领导了一项全国性的姑息治疗医疗实践,并实施和发展了新的临床模式和业务线。在此之前,罗斯曼博士于2015年1月至2018年12月担任KindredHealthcare,Inc.企业首席医疗官他也曾担任Kindred’;的护理中心部门的首席医疗官(从2011年11月到2014年12月),在那里他最终领导医疗和药房领导团队。Rothman博士拥有纽约大学医学院(New York University School of Medicine)的医学博士学位和麦迪逊威斯康星大学(University of Wisconsin,Madison)的哲学学士学位。他完成了耶鲁大学纽黑文医院(Yale New Haven Hospital)的研究生临床培训,并在内科、老年病学和临终关怀与姑息医学三个专业获得三个学位。
Marc Rothman has served as Chief Medical Officer of the Company since June 2020. Prior to this, Dr. Rothman served as Deputy Chief Medical Officer at Aspire Healthcare from May 2019 to June 2020 where he led a nationwide palliative care medical practice and implemented and grew new clinical models and business lines. Before that Dr. Rothman served as Enterprise Chief Medical Officer from January 2015 to December 2018 at Kindred Healthcare, Inc. He also served as the Chief Medical Officer of Kindred’s Nursing Center Division from November 2011 to December 2014 where he eventually led the medical and pharmacy leadership team. Dr. Rothman holds an MD from New York University School of Medicine and a BA in Philosophy from the University of Wisconsin, Madison. He completed his postgraduate clinical training at Yale New Haven Hospital and is triple boarded in Internal, Geriatric and Hospice & Palliative Medicine.
Peter Boumenot

Peter Boumenot自2020年1月起担任公司首席产品官。在此之前,Boumenot先生于2019年8月至2020年1月担任高级副总裁,Product&Operations-Signify Community of the Company。在此之前,布梅诺特曾在AthenaHealth任职9年,从2017年10月到2019年7月担任产品管理Vice President,领导患者参与、人口健康和收入周期服务,在此之前,他担任Vice President,2014年3月至2017年10月,他曾担任客户解决方案集团,以及解决方案设计总监(2012年3月至2014年3月),在那里他曾领导所有业务部门的全面预售至上市后商业组织。Boumenot先生拥有波士顿学院(Boston College)生物学学士学位。


Peter Boumenot has served as Chief Product Officer of the Company since January 2020. Prior to this, Mr. Boumenot served as Senior Vice President, Product & Operations-Signify Community of the Company from August 2019 to January 2020. Prior to this, Mr. Boumenot was at athenahealth for nine years, serving as Vice President, Product Management from October 2017 to July 2019 leading patient engagement, population health and revenue cycle services and prior to that was Vice President, Client Solution Group from March 2014 to October 2017 and Director, Solution Design from March 2012 to March 2014 where he led a comprehensive pre-sale to post-go-live commercial organization of across all business segments. Mr. Boumenot holds a BS in Biology from Boston College.
Peter Boumenot自2020年1月起担任公司首席产品官。在此之前,Boumenot先生于2019年8月至2020年1月担任高级副总裁,Product&Operations-Signify Community of the Company。在此之前,布梅诺特曾在AthenaHealth任职9年,从2017年10月到2019年7月担任产品管理Vice President,领导患者参与、人口健康和收入周期服务,在此之前,他担任Vice President,2014年3月至2017年10月,他曾担任客户解决方案集团,以及解决方案设计总监(2012年3月至2014年3月),在那里他曾领导所有业务部门的全面预售至上市后商业组织。Boumenot先生拥有波士顿学院(Boston College)生物学学士学位。
Peter Boumenot has served as Chief Product Officer of the Company since January 2020. Prior to this, Mr. Boumenot served as Senior Vice President, Product & Operations-Signify Community of the Company from August 2019 to January 2020. Prior to this, Mr. Boumenot was at athenahealth for nine years, serving as Vice President, Product Management from October 2017 to July 2019 leading patient engagement, population health and revenue cycle services and prior to that was Vice President, Client Solution Group from March 2014 to October 2017 and Director, Solution Design from March 2012 to March 2014 where he led a comprehensive pre-sale to post-go-live commercial organization of across all business segments. Mr. Boumenot holds a BS in Biology from Boston College.
David Pierre

David Pierre自2017年12月起担任公司首席运营官。在此之前,Pierre先生于2016年12月至2017年12月担任Advance Health的首席运营官,在那里他推动了运营规模,直到该公司成功出售和合并,形成了Signify Health。皮埃尔先生于2007年8月至2016年12月在塞纳公司担任多个职位,包括Vice President,总经理兼董事总经理,在那里他领导了塞纳公司的多个业务部门,包括医院运营和儿科。他是美国梦百合管理人员学院的院士。Pierre先生拥有芝加哥大学布斯商学院(University of Chicago Booth School of Business)工商管理硕士学位和南卫理公会大学(Southern Methodist University)心理学学士学位。


David Pierre has served as Chief Operating Officer of the Company since December 2017. Prior to this, Mr. Pierre served as Chief Operating Officer of Advance Health from December 2016 to December 2017 where he drove operating scale until its successful sale and merger, which formed Signify Health. Mr. Pierre was at Cerner Corporation from August 2007 to December 2016 in various positions, including Vice President, General Manager and Managing Director, where he led several of Cerner Corporation’s business units, including Hospital Operations and Pediatrics. He is a Fellow of the American College of Healthcare Executives. Mr. Pierre holds an MBA from the University of Chicago Booth School of Business and a BA in Psychology from Southern Methodist University.
David Pierre自2017年12月起担任公司首席运营官。在此之前,Pierre先生于2016年12月至2017年12月担任Advance Health的首席运营官,在那里他推动了运营规模,直到该公司成功出售和合并,形成了Signify Health。皮埃尔先生于2007年8月至2016年12月在塞纳公司担任多个职位,包括Vice President,总经理兼董事总经理,在那里他领导了塞纳公司的多个业务部门,包括医院运营和儿科。他是美国梦百合管理人员学院的院士。Pierre先生拥有芝加哥大学布斯商学院(University of Chicago Booth School of Business)工商管理硕士学位和南卫理公会大学(Southern Methodist University)心理学学士学位。
David Pierre has served as Chief Operating Officer of the Company since December 2017. Prior to this, Mr. Pierre served as Chief Operating Officer of Advance Health from December 2016 to December 2017 where he drove operating scale until its successful sale and merger, which formed Signify Health. Mr. Pierre was at Cerner Corporation from August 2007 to December 2016 in various positions, including Vice President, General Manager and Managing Director, where he led several of Cerner Corporation’s business units, including Hospital Operations and Pediatrics. He is a Fellow of the American College of Healthcare Executives. Mr. Pierre holds an MBA from the University of Chicago Booth School of Business and a BA in Psychology from Southern Methodist University.
Josh Builder

Josh Builder自2020年6月起担任公司首席技术官。在此之前,Builder先生于2016年8月至2020年5月担任Rent the Runway的首席技术与产品官,负责客户体验,运营扩展,供应链技术和数据工程的开发。在此之前,他曾担任SoulCycle公司的首席技术官(2015年6月至2016年7月),在那里他负责构建其技术平台、产品组织和客户数据分析。在此之前,Builder曾在果园工作,2010年1月至2015年6月担任首席技术官,2006年11月至2010年1月担任产品开发&Engineering全球运营Vice President和高级总监,领导该公司的产品管理业务,合并和收购职能以及私有化交易。Builder先生拥有卡内基梅隆大学(Carnegie Mellon University)的计算机信息与决策系统与金融经济学学士学位。


Josh Builder has served as Chief Technology Officer of the Company since June 2020. Prior to this, Mr. Builder served as Chief Technology & Product Officer of Rent the Runway from August 2016 to May 2020 where he was responsible for the customer experience, operational expansion, development of supply chain technology and data engineering. Before that, from June 2015 to July 2016 Mr. Builder was the Chief Technology Officer of Soulcycle where he was responsible for building its technology platform, product organization and customer data analytics. Prior to this, Mr. Builder was at The Orchard, serving as Chief Technology Officer from January 2010 to June 2015 and Vice President and Senior Director, Global Operations, Product Development & Engineering from November 2006 to January 2010 where he led its product management operations, mergers and acquisitions functions and go-private transaction. Mr. Builder holds a BA in Computer Information & Decision Systems & Financial Economics from Carnegie Mellon University.
Josh Builder自2020年6月起担任公司首席技术官。在此之前,Builder先生于2016年8月至2020年5月担任Rent the Runway的首席技术与产品官,负责客户体验,运营扩展,供应链技术和数据工程的开发。在此之前,他曾担任SoulCycle公司的首席技术官(2015年6月至2016年7月),在那里他负责构建其技术平台、产品组织和客户数据分析。在此之前,Builder曾在果园工作,2010年1月至2015年6月担任首席技术官,2006年11月至2010年1月担任产品开发&Engineering全球运营Vice President和高级总监,领导该公司的产品管理业务,合并和收购职能以及私有化交易。Builder先生拥有卡内基梅隆大学(Carnegie Mellon University)的计算机信息与决策系统与金融经济学学士学位。
Josh Builder has served as Chief Technology Officer of the Company since June 2020. Prior to this, Mr. Builder served as Chief Technology & Product Officer of Rent the Runway from August 2016 to May 2020 where he was responsible for the customer experience, operational expansion, development of supply chain technology and data engineering. Before that, from June 2015 to July 2016 Mr. Builder was the Chief Technology Officer of Soulcycle where he was responsible for building its technology platform, product organization and customer data analytics. Prior to this, Mr. Builder was at The Orchard, serving as Chief Technology Officer from January 2010 to June 2015 and Vice President and Senior Director, Global Operations, Product Development & Engineering from November 2006 to January 2010 where he led its product management operations, mergers and acquisitions functions and go-private transaction. Mr. Builder holds a BA in Computer Information & Decision Systems & Financial Economics from Carnegie Mellon University.
Laurel Douty

Laurel Douty自2020年2月起担任公司执行Vice President、临床运营和护理服务。在此之前,Douty女士于2019年1月至2020年2月担任独立顾问,专注于为一家大型私募股权拥有的视觉公司设计和实施临床管理式护理基础设施。在她的独立咨询之前,Douty女士在麦哲伦健康公司(Magellan Health)工作了近11年,在她的任期内责任越来越大。Douty女士于2008年3月至2015年6月在Magellan Health Specialty Division任职,晋升为首席运营官兼临床和服务运营高级副总裁。从2015年7月到2018年12月,Douty’;女士的职位扩展到更广泛的麦哲伦医疗保健部门的首席运营官和首席经验官,其中包括以下部门:专科医疗/外科手术,行为健康,员工援助计划,ACO和提供者护理协调,医疗补助/医疗保险健康计划和专科药房索赔。在麦哲伦任职期间,Douty’;女士的运营管理包括直接领导服务和临床运营,网络承包和网络运营管理,索赔付款和付款完整性,创新和实施PMO以及部门资本支出管理。Douty女士持有the University of Texas at Arlington政治学学士学位。


Laurel Douty has served as Executive Vice President, Clinical Operations, Episodes of Care Services of the Company since February 2020. Prior to this, Ms. Douty was an independent consultant from January 2019 to February 2020 focused on designing and implementing a clinical managed care infrastructure for a large private equity-owned vision company. Prior to her independent consulting, Ms. Douty was at Magellan Health for almost 11 years with increasing responsibilities during her tenure. Ms. Douty started at Magellan Health in the specialty division from March 2008 to June 2015 progressing to Chief Operating Officer and Senior Vice President of Clinical and Service Operations. From July 2015 through December 2018 Ms. Douty’s role was expanded to Chief Operating Officer and Chief Experience Officer for the broader Magellan Health Care division, which included the following segments: Specialty Medical/Surgical, Behavioral Health, Employee Assistance Programs, ACO and provider care coordination, Medicaid/Medicare health plan and specialty pharmacy claims. Ms. Douty’s operational management during her tenure at Magellan included direct leadership of service and clinical operations, network contracting and network operations management, claims payment and payment integrity, innovation and implementation PMO, and divisional capital expenditure management. Ms. Douty holds a BA in Political Science from the University of Texas at Arlington.
Laurel Douty自2020年2月起担任公司执行Vice President、临床运营和护理服务。在此之前,Douty女士于2019年1月至2020年2月担任独立顾问,专注于为一家大型私募股权拥有的视觉公司设计和实施临床管理式护理基础设施。在她的独立咨询之前,Douty女士在麦哲伦健康公司(Magellan Health)工作了近11年,在她的任期内责任越来越大。Douty女士于2008年3月至2015年6月在Magellan Health Specialty Division任职,晋升为首席运营官兼临床和服务运营高级副总裁。从2015年7月到2018年12月,Douty’;女士的职位扩展到更广泛的麦哲伦医疗保健部门的首席运营官和首席经验官,其中包括以下部门:专科医疗/外科手术,行为健康,员工援助计划,ACO和提供者护理协调,医疗补助/医疗保险健康计划和专科药房索赔。在麦哲伦任职期间,Douty’;女士的运营管理包括直接领导服务和临床运营,网络承包和网络运营管理,索赔付款和付款完整性,创新和实施PMO以及部门资本支出管理。Douty女士持有the University of Texas at Arlington政治学学士学位。
Laurel Douty has served as Executive Vice President, Clinical Operations, Episodes of Care Services of the Company since February 2020. Prior to this, Ms. Douty was an independent consultant from January 2019 to February 2020 focused on designing and implementing a clinical managed care infrastructure for a large private equity-owned vision company. Prior to her independent consulting, Ms. Douty was at Magellan Health for almost 11 years with increasing responsibilities during her tenure. Ms. Douty started at Magellan Health in the specialty division from March 2008 to June 2015 progressing to Chief Operating Officer and Senior Vice President of Clinical and Service Operations. From July 2015 through December 2018 Ms. Douty’s role was expanded to Chief Operating Officer and Chief Experience Officer for the broader Magellan Health Care division, which included the following segments: Specialty Medical/Surgical, Behavioral Health, Employee Assistance Programs, ACO and provider care coordination, Medicaid/Medicare health plan and specialty pharmacy claims. Ms. Douty’s operational management during her tenure at Magellan included direct leadership of service and clinical operations, network contracting and network operations management, claims payment and payment integrity, innovation and implementation PMO, and divisional capital expenditure management. Ms. Douty holds a BA in Political Science from the University of Texas at Arlington.